In this context, different settings (metastatic vs. neoadjuvant), different assays (% of PD-L1+ immune cells and/or tumor cells, CPS, semiquantitative scores), different immune checkpoint inhibitors (anti-PD-L1 vs. anti-PD1) and different chemotherapeutic partners may have played a role in the generation of such inconclusive and inconsistent data [68]. Here, CD274 is linked to neoplasm.